There is currently no generic Banzel (rufinamide) available, as the medication is protected by a patent that prevents any generic versions from being manufactured. The patent is set to expire in August 2020, at which time a generic form may become available. However, lawsuits or other patents for specific uses may extend or shorten the date by which a generic version becomes available.
Is a Generic Version of Banzel Available?Banzel™ (rufinamide) is a prescription seizure medication. It is approved for use in adults and children age four and over who have a certain type of epilepsy known as Lennox-Gastaut syndrome.
Banzel is manufactured by Eisai Co., Ltd. It is currently under the protection of exclusivity rights that prevent any generic versions of Banzel from being manufactured in the United States.
When Will Generic Banzel Be Available?
The patent for Banzel is currently set to expire in August 2020. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as lawsuits or other Banzel patents. Once the medication goes off-patent, several companies may begin manufacturing a generic Banzel drug.